Related to Exploring New Ways to Get at Old Bacterial Targets to Combat Resistant Strains

• Genmab and GSK Achieve Accelerated FDA Clearance of CLL Drug
  
• FDA Approves AdvanDx’ Faster PNA FISH Protocol for Identifying Enterococcal Bloodstream Pathogens
  
• Biosearch Grants Micronics Rights to Its Nucleic Acid Assay Chemistries
  
• Crucell Taps Calmune for Discovery Work in Infectious Diseases
  
• GSK Signs On Astex in Broad Partnership for About $33M Up Front
  
• PPD and Janssen Ally on Therapies for Irritable Bowel Syndrome and Bacterial Infections
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Good and Bad News at Idera
  
• Galapagos Achieves $5.9M Milestone in Arthritis Deal with GSK
  
• GSK Pays Galapagos $9.45M to Broaden Scope of Arthritis Deal
  
• Seattle Genetics Receives $12M Up Front in Deal with GSK
  
• KaloBios Obtains $35M Up Front from Sanofi Pasteur for Clinical Antibody Candidate against Pseudomonas Aeruginosa
  
• Rentschler to Manufacture Kenta’s Human mAb against MRSA for Clinical Trials
  
• GlobeImmune Raises $17.5M in Series E Financing
  
• GSK Pays Apeiron About $17.5M Up Front for Early Clinical-Stage ACE2 Candidate
  
• Dynavax and GSK Choose Clinical Candidate from Endosomal TLR Inhibitor Program
  
• GSK and Regulus to Collaborate on miRNA-Based HCV Drugs
  
• Cellzome Pockets $33M Up Front in Second Drug Discovery Collaboration with GSK for Inflammatory Diseases
  
• GSK to Use Gentronix’ GreenScreen HC and BlueScreen HC Genotoxicity Assays
  
• Human Genome Sciences and GSK’s Lupus Candidate Hits the Mark in Second Phase III Trial